NGNE
NASDAQ HealthcareNeurogene Inc. - Common Stock
Biotechnology
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.
๐ Market Data
| Price | $26.85 |
|---|---|
| Volume | 130,562 |
| Market Cap | 419.28M |
| Beta | 1.890 |
| RSI (14-Day) | 77.8 Overbought |
| 200-Day MA | $21.82 |
| 50-Day MA | $22.41 |
| 52-Week High | $37.27 |
| 52-Week Low | $11.77 |
| Forward P/E | -5.03 |
| Price / Book | 1.57 |
๐ฏ Investment Strategy Scores
NGNE scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Over-Hyped (93/100) โ this strategy Overbought stocks (potential short candidates).
Lowest fit among scored strategies: ๐ฐ Dividend Daddy (7/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find NGNE in your text
Paste any article, transcript, or post โ the tool will extract NGNE and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.